The 28[th] of March is the last day of trading in TO 2

The exercise period for Prostatype Genomics AB's ("Prostatype Genomics" or "the Company") warrants of series TO 2 ("TO 2") lasts until March 30, 2023, and the last day for trading in TO 2 is March 28, 2023. Holders of TO 2 have the right to subscribe for one new share in Prostatype Genomics at a price of SEK 2.90 per share for each warrant. An information sheet is available on the respective websites of Prostatype Genomics (www.prostatypegenomics.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

TO 2 in brief

Exercise price: each TO 2 gives the holder the right to subscribe for one (1) new share in Prostatype Genomics at a price of SEK 2.90 per share.
Issue amount: there are 7,755,895 outstanding TO 2. At full exercise of all TO 2’s Prostatype Genomics will receive approx. SEK 22.5 million before transaction related costs.
Outstanding shares in Prostatype prior to warrant exercise: 22,859,497 shares.
Ticker and ISIN: TO 2 are traded on Nasdaq First North Growth Market under the ticker ”PROGEN TO2” and ISIN-code SE0018220014.
Upon full exercise of TO 2, the number of shares in Prostatype Genomics will increase by 7,755,895 shares to 30,615,392 shares and the share capital will increase by SEK 465,353.70 to SEK 1,836,923.52. This entails a dilution of approximately 25 percent based on the number of outstanding shares in Prostatype Genomics after full utilization of TO 2.

Advisors and issuing agent

Sedermera Corporate Finance AB is the financial advisor and Nordic Issuing AB is the issuing for Prostatype Genomics in connection with the warrant exercise. Markets & Corporate Law Nordic AB is the legal advisor.

For further information about TO 2, please contact

Sedermera Corporate Finance AB

Phone: +46 (0) 40 615 14 10

E-mail: cf@sedermera.se

Webpage: www.sedermera.se

Nordic Issuing AB

Phone: +46 (0) 40 632 00 20

E-mail: info@nordic-issuing.se

Webpage: www.nordic-issuing.se

For further information about Prostatype Genomics, please contact

Nicklas Rosendal

E-mail: nicklas.rosendal@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB

Phone: +46 (0) 11-32 30 732

E-mail: ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision basis for the question of treatment or not treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.